Outlook Therapeutics announced a $5 million registered direct offering of 8.54 million shares at $0.5855 each to its largest shareholder, GMS Ventures. The proceeds will support working capital and general corporate purposes, including advancing its retinal disease drug ONS-5010/LYTENAVA™. The company also amended warrants to reduce exercise prices, enhancing shareholder value. This funding move supports ongoing development and potential U.S. approval of their ophthalmic bevacizumab formulation for retinal conditions.
The Schall Law Firm is investigating Exzeo Group, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This follows Exzeo's announcement of its Q1 2026 financial results on May 6, 202...
Baker Hughes has locked in multi-year contract extensions with Equinor to support offshore hydrocarbon production in the North Sea and expanded its offshore drilling operations in Brazil's Santos Basin through a contract extension with Petrobras. The...
Ford Motor Company announced the launch of Ford Energy, a subsidiary focused on large-scale battery storage systems for utilities, industrial clients, and AI data centers. Morgan Stanley valued this new division at $10 billion, projecting annual EBIT...
SpaceX has filed for an IPO that could value the company at $1.75 trillion or more. Several mutual funds and ETFs, including those managed by Baron Capital, Baillie Gifford, and Ark Invest, hold significant stakes in SpaceX, providing investors early...
Bay Area Lyme Foundation raised $900,000 at its LymeAid 2026 gala to support research for better Lyme disease diagnostics and treatments. The event featured the inaugural Neil L. Spector, MD, Legacy Award recognizing transformative research, awarded ...
